Sebia acquires Zeus Scientific
Sebia, a global specialty diagnostic company providing solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, has acquired Zeus Scientific, an in vitro diagnostic (IVD) company based in New Jersey, U.S., specialized in autoimmune and infectious diseases techno-
logies. Financial terms of the agreement are undisclosed.
Zeus Scientific, will provide synergies and expand Sebia’s capabilities and product portfolio in autoimmunity, with a strong footprint in the United States.
“Through this acquisition, we will be able to expand Sebia’s capabilities to provide high-value solutions to our customers and patients,” said Jean-Marc Chermette, Sebia’s president and CEO. “Zeus Scientific has developed strong expertise in autoimmunity and infectious diseases. There are many parallels in our respective R&D programmes, as well as benefits for the development of our global commercial network. With this acquisition, Sebia is reinforcing its operations and footprint in the United States, the largest IVD market. I am very pleased to welcome Zeus Scientific associates to the Sebia Group and look forward to a strong collaboration to accelerate innovation and global growth.”
Zeus Scientific is a global company focusing on the development, production and marketing of in vitro diagnostic tests to detect autoimmune and infectious diseases, available in several different technology applications. Clinical areas include inflammatory rheumatic diseases, serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology and a number of infectious diseases, with a strong focus on Lyme disease.
Founded in 1967, Sebia is a world-leadingprovider of clinical protein electrophoresis equipment and reagents, a technology used for IVD testing. Its systems analyze proteins in order to screen and monitor various diseases and conditions; primarily oncology (multiple myeloma) and metabolic disorders such as diabetes, as well as hemoglobinopathy and rare pathologies. Following the acquisition of Orgentec, Corgenix and Arotec in 2021, Sebia now develops and markets solutions
for autoimmunity diagnostics.